These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ruggenenti P; Perna A; Benini R; Remuzzi G J Am Soc Nephrol; 1998 Nov; 9(11):2096-101. PubMed ID: 9808096 [TBL] [Abstract][Full Text] [Related]
8. Update on calcium antagonists and the kidney. Tobe S Curr Opin Nephrol Hypertens; 2003 May; 12(3):309-15. PubMed ID: 12698071 [TBL] [Abstract][Full Text] [Related]
9. Angiotensin converting enzyme inhibition and calcium channel blockade in incipient diabetic nephropathy. The Melbourne Diabetic Nephropathy Study Group. Jerums G; Allen TJ; Tsalamandris C; Cooper ME Kidney Int; 1992 Apr; 41(4):904-11. PubMed ID: 1513112 [TBL] [Abstract][Full Text] [Related]
10. [Do angiotensin converting enzyme and calcium channel blocker intervene in the progression of renal disease besides by lowering systemic hypertension?]. Nagase M Nihon Rinsho; 1997 Aug; 55(8):2116-22. PubMed ID: 9284433 [TBL] [Abstract][Full Text] [Related]
11. Converting enzyme inhibitors and calcium antagonists in the long-term treatment of hypertension in chronic renal failure. Lenz T; August P Wien Klin Wochenschr; 1990 May; 102(11):315-9. PubMed ID: 2195780 [TBL] [Abstract][Full Text] [Related]
12. Renal protection in diabetes--an emerging role for calcium antagonists. Parving HH; Tarnow L; Rossing P Cardiology; 1997; 88 Suppl 3():56-62. PubMed ID: 9397296 [TBL] [Abstract][Full Text] [Related]
14. The antiproteinuric effects of blood pressure-lowering agents: differences between nondiabetics and diabetics. de Jong PE; Heeg JE; Apperloo AJ; de Zeeuw D J Cardiovasc Pharmacol; 1992; 19 Suppl 6():S28-32. PubMed ID: 1382162 [TBL] [Abstract][Full Text] [Related]
15. Renal protection in diabetes: an emerging role for calcium antagonists. Parving HH; Tarnow L; Rossing P J Hypertens Suppl; 1996 Nov; 14(4):S21-5. PubMed ID: 8986939 [TBL] [Abstract][Full Text] [Related]
16. Compelling drug indications in diabetic and nondiabetic nephropathy. Ritz E; Dikow R; Zeier M Curr Hypertens Rep; 2004 Aug; 6(4):293-9. PubMed ID: 15257864 [TBL] [Abstract][Full Text] [Related]
17. Renoprotective effects of antihypertensive drugs. Preston RA Am J Hypertens; 1999 Jan; 12(1 Pt 2):19S-32S. PubMed ID: 10077416 [TBL] [Abstract][Full Text] [Related]
19. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance? Vogt L; Kocks MJ; Laverman GD; Navis G Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515 [TBL] [Abstract][Full Text] [Related]
20. Calcium antagonists and the diabetic hypertensive patient. Parving HH; Rossing P Am J Kidney Dis; 1993 Jun; 21(6 Suppl 3):47-52. PubMed ID: 8503435 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]